Products

EchoNext
Pathway Labs
Cardiology AI
EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

See all 1 product →

About Pathway Labs

Pathway Labs is a healthcare AI company focused on transforming clinical workflows and improving patient outcomes through advanced artificial intelligence. Their core offering involves AI-powered platforms designed to integrate seamlessly into existing healthcare systems, providing actionable insights and automating routine tasks. This allows physicians to dedicate more time to direct patient care and complex decision-making, reducing administrative burden and potential for burnout. The company’s solutions are built to be interoperable and scalable, addressing critical needs in areas such as diagnostic support, personalized treatment planning, and operational efficiency within healthcare organizations.

Pathway Labs emphasizes the development of explainable AI, ensuring that their algorithms provide transparent and interpretable results, which is crucial for physician trust and clinical adoption. Their technology aims to augment human intelligence rather than replace it, offering tools that can analyze vast amounts of medical data, identify patterns, and flag anomalies that might be missed by human observation alone. By leveraging machine learning and natural language processing, Pathway Labs seeks to unlock new efficiencies and insights across the healthcare continuum, from early disease detection to chronic disease management.

What Physicians Need to Know

Specialization: AI for Clinical Decision Support
Pathway Labs specializes in developing AI tools that provide clinical decision support, aiming to assist physicians in making informed treatment decisions. Their AI model, EchoNext, has received FDA approval for detecting six types of hidden structural heart disease from electrocardiograms. They also focus on creating AI systems that offer transparent, just-in-time reasoning, linking recommendations to expert-vetted guidelines and drug references.
Specialization: Advanced Diagnostic Services
Pathway Diagnostic Laboratories, a related entity, offers comprehensive genetic testing using advanced technologies like PCR testing and Next Generation Sequencing (NGS). They provide precise and timely results for disease detection, monitoring, and treatment planning, with a focus on accuracy, speed, and patient safety.
Key Differentiator: Transparent and Evidenced-Based AI
Pathway's AI stands out due to its transparent just-in-time reasoning pipeline, which combines retrieval-augmented generation (RAG) with chain-of-thought (CoT) analysis and agentic tool calling. This architecture allows the AI to evaluate multiple information sources, identify knowledge gaps, generate follow-up questions, and apply clinical scoring rules, all while revealing its step-by-step reasoning and linking recommendations to verifiable evidence.
Key Differentiator: High Accuracy and Performance
Pathway's proprietary large-language model (LLM), 'Deep,' achieved a 96% accuracy rate on a validated set of United States Medical Licensing Examination (USMLE) questions, outperforming other medical AI systems and generalist systems.
Technology Stack: Live Data Framework for AI
Pathway Labs utilizes a 'Live Data Framework' designed for real-time data processing and AI. This framework facilitates data ingestion from over 300 sources with automatic synchronization, enabling the creation of applications that serve real-time features, live vector search, and anomaly alerts. It aims to provide accurate AI insights from large volumes of connected documents and data without requiring vector databases or a complex stack.
Technology Stack: Compliance-First AI Governance
Pathway Labs builds compliance-first applications, data pipelines, and AI governance with features like role-based access, policy rules, and event logging built into the platform. This ensures secure, stable, and compliant systems, particularly important for sensitive environments and mission-critical organizations.
Physician Tip

For physicians, Pathway Labs offers AI tools that can significantly enhance diagnostic capabilities, particularly in cardiology with FDA-approved tools like EchoNext for structural heart disease detection. The transparent and evidence-based reasoning of their AI models means you can trust the recommendations, as they are linked to expert-vetted guidelines and drug references. The high accuracy on medical licensing exams also suggests a reliable tool for clinical decision support. Additionally, for those utilizing genetic testing, Pathway Diagnostic Laboratories provides comprehensive and timely results to support personalized care. The integration capabilities with existing systems can reduce administrative burden and streamline workflows, allowing more time for patient care.

Pathway Labs' MyPath platform integrates with Learning Management Systems (LMS) and third-party Financial Aid processors, syncing data in real-time or nightly to reduce administrative burden. They also offer integrations with Dropbox Sign for e-signatures and a Leads API for syncing inquiries from websites. For laboratory operations, Pathways LIS supports various inputs like web APIs, QR codes, HL7 file uploads, and Excel batch uploads, and outputs to printed reports, faxes, emails, SMS, WhatsApp, and Electronic Health Record Sharing Systems (eHealth). Their partnership with OpenEvidence will also expand the reach of their AI tools, as OpenEvidence is widely used by U.S. physicians and offers clinical decision support, real-time documentation, and medical literature synthesis.

Products by Pathway Labs

1 product in the directory

EchoNext
Pathway Labs
Cardiology AI
EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What the Web Says

Pathway Labs offers a Student Information System (SIS) primarily for clock-hour and trade schools, aiming to streamline student lifecycle management from admissions to graduation. Users generally praise its customer service, ease of use, and ability to consolidate student information and track progress efficiently.

Overall: Positive

Strengths

  • Excellent customer service and support.
  • Streamlines workflows and digitizes admissions processes.
  • Efficiently tracks student progress, attendance, and hours.
  • Consolidates student information from various sources into one platform.
  • Easy to implement and user-friendly.
  • Continuously evolving with new features.

Limitations

  • Occasional visual glitches that can be resolved by refreshing the site.
  • Some reviews for similarly named companies indicate issues with management, workload, and pay, though these are not directly attributed to Pathway Labs (SIS).
  • The score for this software has declined over the past month on Crozdesk.

Based on reviews from: G2, Crozdesk, SoftwareAdvice GB

Last updated: 2026-07-02

Videos

News, demos, and interviews about Pathway Labs.

Loading videos...

Videos load interactively. If none appear, search YouTube for Pathway Labs →

View all on YouTube

Press & Coverage

Business Wire
Pathway Labs Announces World's First FDA Clearance for Multicondition AI in Cardiology and Partnership with OpenEvidence
Pathway Labs publicly launched EchoNext, the world's first FDA-approved AI detection tool for flagging high-risk structural heart diseases from standard 12-lead electrocardiograms (ECGs), receiving clearance for six indications. The company also announced a partnership with OpenEvidence to make EchoNext available on their AI platform, used by over half of US clinicians.
2026-06
HLTH
Pathway Labs Raises $8.5M and Launches FDA-Approved EchoNext AI to Detect Hidden Heart Disease from ECGs
Pathway Labs announced an $8.5 million seed financing round led by AlleyCorp and Breyer Capital, coinciding with the launch of EchoNext, an FDA-approved AI platform for identifying patients at high risk for structural heart disease using ECGs. This funding will support commercialization and broader deployment of the technology.
2026-06
Medical Economics
FDA-cleared AI tool flags hidden heart disease from a standard ECG
Pathway Labs' EchoNext, a newly FDA-cleared AI tool, can detect structural heart disease from routine 12-lead ECGs, identifying conditions that often go undiagnosed. The tool received FDA clearance for six indications, including right- and left-sided heart failure and valve disease.
2026-06
NewYork-Presbyterian Hospital
AI Tool Developed at NewYork-Presbyterian and Columbia to Detect Hidden Heart Disease Receives FDA Approval
EchoNext, an AI tool developed by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center, has received the world's first FDA clearance for AI detection of hidden heart disease through ECGs. This technology offers a new approach to screening for structural heart disease.
2026-06
The Star
Doctors thought it was asthma. AI flagged a serious heart problem.
A case published in Nature Medicine on June 22, 2026, described EchoNext detecting previously undiagnosed heart failure in a patient, Louie Quiros, which ultimately led to the world's first heart transplant due to AI detection of disease. This highlights AI's power in addressing missed diagnoses.
2026-06
Traders Union
Breyer Capital leads Pathway Labs funding for multi-condition AI heart diagnostics
Breyer Capital has led the first institutional investment in Pathway Labs, which recently obtained FDA clearance for its multi-condition AI cardiology system, EchoNext. This funding will advance the platform designed to detect structural heart disease using standard ECG data.
2026-06
BioPharma BoardRoom
Pathway Labs Launches FDA-Cleared AI ECG Tool for Early Detection of Structural Heart Disease
Pathway Labs has publicly launched EchoNext, an FDA-approved AI detection tool that analyzes standard 12-lead ECGs to identify high-risk structural heart diseases. This makes EchoNext the first FDA-approved AI platform to identify multiple high-risk cardiac conditions from standard ECGs.
2026-06
TechTarget
OpenEvidence brings AI-powered heart disease detection to doctors
Doctors using OpenEvidence's AI-based clinical decision support platform will soon have access to EchoNext, an AI tool from Pathway Labs that can flag six types of structural heart disease from ECGs. This partnership aims to expand the tool's reach to nearly two-thirds of U.S. physicians.
2026-06

Frequently Asked Questions

Pathway Labs offers EchoNext, an FDA-cleared AI screening tool that analyzes standard 12-lead electrocardiograms (ECGs) to detect signs of structural heart disease. It is cleared to identify six different types of heart disease, including right and left-sided heart failure, valve disease, severe hypertrophy compatible with infiltrative cardiomyopathy, and pulmonary hypertension.
Pathway Labs' EchoNext tool has received FDA clearance for its multi-condition AI system in cardiology, indicating it meets regulatory standards for safety and effectiveness. While specific details on HIPAA compliance for EchoNext aren't explicitly stated in the provided information, another company named Pathway (which may or may not be related) has introduced HIPAA-compliant access for its subscribers, supporting secure use of patient-specific information in AI queries.
The provided information does not detail the pricing structure for Pathway Labs' healthcare AI solutions like EchoNext for hospitals or clinics. However, a separate entity also named Pathway Labs, which focuses on school IT solutions, lists tiered pricing plans ranging from $600/month for basic features to custom plans for larger institutions, with a 10% implementation and onboarding fee. It's important to note that this pricing may not be applicable to the healthcare AI products.
While specific support details for Pathway Labs' healthcare AI are not extensively outlined, their partnership with OpenEvidence aims to expand access to EchoNext, making it available on a platform used by a significant number of US clinicians. This suggests that support may be integrated through the OpenEvidence platform, which offers clinical decision support and other features.
Pathway Labs has partnered with OpenEvidence to expand access to its EchoNext algorithm throughout the United States. OpenEvidence is an AI platform regularly used by over half of US clinicians, which will help integrate EchoNext into existing clinical workflows.
Pathway Labs has recently secured $8.5 million in seed funding led by AlleyCorp and Breyer Capital to expand its reach, support R&D, and deploy its technology across health systems. The company was founded by cardiologist Dr. Pierre Elias, who also serves as CEO and Medical Director for AI at NewYork-Presbyterian. Rachel Katz is the co-founder and Chief Operating Officer.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.